CharlesAlanSchifferMD

Oncology • Detroit, MI

Hematologic Oncology

Professor, Internal Medicine, Wayne State University School of Medicine

Join to view full profile

Dr. Schiffer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schiffer's full profile

Already have an account?

Office
4100 John R St
Detroit, MI 48201
Phone+1 800-527-6266

Fax+1 313-576-8767

Education & Training

NYU Grossman School of MedicineResidency, Internal Medicine, 1968 - 1972
New York University School of MedicineClass of 1968

Certifications & Licensure

MI State Medical License 1997 - 2025
MD State Medical License 1975 - 1997
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2010
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Trial to Reduce Alloimmunization to Platelets (TRAP) Start of enrollment: 1989 Aug 01
Completed
Phase 3
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2001 Aug 01
Completed
Phase 2
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 2003 Jun 01
Completed
Phase 1
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Start of enrollment: 2015 Feb 12
Terminated
Phase 1
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Start of enrollment: 2012 May 01
Terminated
Phase 1
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Start of enrollment: 2013 Apr 30
Active, not recruiting
Phase 2
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma Start of enrollment: 2020 Aug 17
Suspended
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1399 citations
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland
Journal of Clinical Oncology. 2002-05-15
1297 citations
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson, Peter L. Greenberg, John M. Bennett, Bob Löwenberg, Pierre W. Wijermans
Blood. 2006-07-15
1120 citations
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage
Journal of Clinical Oncology. 2006-07-01

Journal Articles

Promoting Apoptosis with Venetoclax — A Benefit for Older Patients with AML
Charles Schiffer, MD, The New England Journal of Medicine

Abstracts/Posters

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Charles A. Schiffer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Charles A. Schiffer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics
Charles A. Schiffer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Other

To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...
Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2013-03-20
To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...
Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2013-01-03
To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...
Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2012-02-14
To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...
Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2012-12-03
To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...
Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2012-09-25
To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...
Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2012-05-07
Join now to see all

Authored Content

Promoting Apoptosis with Venetoclax — A Benefit for Older Patients with AMLAugust 2020

Press Mentions

Combo Protocol Promising for Older AML PatientsAugust 13th, 2020

Grant Support

Transfusion Trial To Prevent Platelet AlloimmunizationNational Heart, Lung, And Blood Institute1994–1995
Mechanisms Of Drug Resistance In Acute Myeloid LeukemiaNational Cancer Institute1990–1994
Transfusion Trial To Prevent Platelet AllolimmunizationNational Heart, Lung, And Blood Institute1989–1993
Mechanisms Of Platelet RefractorinessNational Heart, Lung, And Blood Institute1986–1988